Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong financial health and strategic growth, with raised revenue guidance and successful product developments. Despite competitive pressures and litigation uncertainties, the company maintains robust cash reserves. The Q&A section highlights a proactive approach to potential risks, with strategic settlements and ongoing R&D investments. The raised revenue guidance and strategic pipeline advancements contribute to a positive outlook, likely resulting in a 2-8% stock price increase.
Key Financial Performance
Q4 2025 Net Product Revenue $243.8 million, up from $201.3 million in the same period last year, representing a 21% increase. The growth was driven by strong demand for WAKIX due to its broad clinical utility and effective commercial execution.
Full Year 2025 Net Product Revenue $868.5 million, showing strong year-over-year growth and marking 6 consecutive years of revenue growth and profitability. The increase reflects sustained demand and market opportunity for WAKIX.
Q4 2025 Operating Expenses $136.7 million, compared to $91.1 million in Q4 2024. The 50% increase was attributed to investments in R&D for late-stage pipeline advancement, commercialization of WAKIX, and ANDA litigation and settlement expenses.
Q4 2025 Non-GAAP Adjusted Net Income $33.4 million or $0.57 per diluted share, compared to $64.2 million or $1.10 per diluted share in Q4 2024. The decline was due to increased investments in R&D and other operational areas.
Cash, Cash Equivalents, and Investments (End of 2025) $882.5 million, reflecting robust cash generation of $348.2 million from operations in 2025. This positions the company well for future investments in pipeline and commercial portfolio expansion.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
WAKIX net product revenue: Achieved $243.8 million in Q4 2025, up from $201.3 million in Q4 2024. Full-year revenue reached $868.5 million, marking six consecutive years of growth. Projected to achieve $1 billion to $1.04 billion in 2026.
Pitolisant GR: On track for NDA submission in Q2 2026 with a target PDUFA date in Q1 2027. Eliminates the need for titration, offering differentiation.
Pitolisant HD: Designed for unique orphan rare CNS indications. Top-line data expected in 2027, with PDUFA in 2028.
New pitolisant formulation: Exploring broader CNS indications, including fatigue in multiple sclerosis, with patent protection until 2042.
Market opportunity for WAKIX: Approximately 80,000 diagnosed narcolepsy patients, with 8,500 average patients currently on WAKIX. Large market potential remains.
Expansion of field-based teams: Increased by 20% to enhance market presence and support growth.
FDA approval for pediatric use: WAKIX approved for cataplexy in patients 6 years and older, expanding its market.
Operational execution: Achieved three consecutive quarters of 400+ average patient adds. Enhanced commercial strategies, including refined messaging and improved patient support processes.
Pipeline advancement: Five ongoing Phase III trials targeting distinct CNS indications. Robust late-stage pipeline with significant progress.
Intellectual property (IP) strategy: Settled with six of seven ANDA filers, delaying generic entry until at least March 2030. Pursuing pediatric exclusivity for additional protection.
Business development: Focus on expanding pipeline and commercial portfolio through strategic investments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Intellectual Property (IP) Risks: The company is engaged in ongoing litigation and settlements with generic filers regarding the WAKIX franchise. While progress has been made, with settlements reached with 6 of the 7 ANDA filers, the legal process is still ongoing, and the outcome remains uncertain. This poses a risk to the exclusivity and revenue potential of WAKIX.
Regulatory and Approval Risks: The company is advancing multiple late-stage clinical trials and preparing for regulatory submissions, including the NDA for pitolisant GR and other pipeline assets. Delays or failures in obtaining regulatory approvals could impact the company's ability to expand its product portfolio and achieve projected growth.
Market Competition: WAKIX faces competitive pressures as it seeks to maintain its unique position as a non-scheduled treatment option. The entry of generics post-2030 or other competitive products could erode market share and revenue.
Supply Chain and Operational Risks: The company is expanding its field-based teams and launching new patient support initiatives. Any disruptions in these operational expansions or inefficiencies in execution could impact the company's ability to sustain growth.
Economic and Seasonal Dynamics: The company anticipates typical seasonal dynamics in Q1 2026, including higher gross-to-net deductions and potential inventory drawdowns. These factors could temporarily impact financial performance.
Pipeline Development Risks: The company has a robust late-stage pipeline with 5 ongoing Phase III trials. However, the success of these trials is uncertain, and any failures could hinder long-term growth and value creation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for WAKIX: Harmony Biosciences projects WAKIX net revenue to reach blockbuster status in 2026, with guidance set at $1 billion to $1.04 billion.
Pipeline Advancements: The company is advancing its late-stage pipeline with 5 ongoing Phase III registrational trials targeting 5 distinct CNS indications, with multiple catalysts expected over the next few years.
Pitolisant GR and HD Development: Pitolisant GR is on track for NDA submission in Q2 2026 and a target PDUFA date in Q1 2027. Pitolisant HD is expected to deliver top-line data in 2027 and a PDUFA in 2028.
New Formulation of Pitolisant: Harmony plans to explore broader CNS indications with a new formulation of pitolisant, focusing on fatigue in multiple sclerosis as the lead indication, with potential applications in post-stroke fatigue and Parkinson's disease.
Pediatric Exclusivity for WAKIX: The company is on track to achieve pediatric exclusivity for WAKIX, which would extend regulatory exclusivity by 6 months, with top-line data from the TEMPO study expected in the second half of 2026.
Epilepsy Franchise: EPX-100 is advancing in two global Phase III registrational programs for Dravet syndrome and Lennox-Gastaut syndrome, with top-line data expected in the first half of 2027 and a PDUFA in 2028.
Orexin-2 Receptor Agonist: BP1.15205 is in a Phase I clinical study, with Phase I PK data expected in mid-2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you comment on the baseline seizure rates and baseline antiseizure medication use for EPX-100 in Dravet syndrome patients? How does it compare to real-world patients and other Dravet clinical trials?
A:The patients in the Dravet syndrome study had treatment-resistant seizures and were on an average of about 4 antiseizure medications. The baseline seizure rates were comparable to other studies, though the exact number was not provided. The study showed a 50% median reduction in seizures, with 50% of patients achieving this reduction. The safety profile was favorable, with minimal gastrointestinal side effects and no significant liver function issues. The liquid formulation and BID dosing regimen were highlighted as advantages.
Q:What is the PK/PD and safety bar for the orexin-2 receptor agonist in Phase I to move into later-stage studies?
A:The Phase I PK study is ongoing, with clinical PK, safety, and tolerability data expected by mid-2026. The company does not anticipate differences from other orexin receptor agonists. The next stage involves a sleep-deprived healthy volunteer study in the second half of the year. Takeda is ahead in the competitive landscape, but the company aims to accelerate development by leveraging learnings from other programs.
Q:Will there be multiple ascending dose data in the second half for the orexin-2 receptor agonist? What are the target indications?
A:The multiple ascending dose study will follow the single ascending dose study, and a sleep-deprived healthy volunteer study will run in parallel. The company is considering indications beyond narcolepsy and idiopathic hypersomnia, including neuropsychiatric disorders like cognition and mood. The competitive landscape will guide further decisions.
Q:What is the company’s strategy if there is an earlier-than-expected loss of exclusivity due to the patent case?
A:The company has settled with 6 of 7 ANDA filers, positioning generic entry at March 2030 if pediatric exclusivity is granted. The company has $880 million in cash and generated $348 million last year, ensuring a strong position to fund programs and bridge to new development assets.
Q:What are the gating factors for filing the pitolisant GR NDA next quarter? How is enrollment progressing for Phase III narcolepsy and IH studies for pitolisant HD?
A:The pitolisant GR NDA submission is on track for Q2 2026, with a PDUFA date in Q1 2027. Enrollment for pitolisant HD studies is progressing despite competition, with top-line data expected in 2027 and a PDUFA in 2028.
Q:What is the commercial strategy for pitolisant GR?
A:The commercial team is preparing for a PDUFA in Q1 2027. The strategy focuses on new patients and recontacting previous patients. The GR formulation allows patients to start at a therapeutic dose, offering faster outcomes and additional protection for the WAKIX franchise.
Q:What caused the increase in SG&A expenses in Q4? Any updates on EPX-200?
A:The increase in SG&A expenses was due to R&D investments for Phase III studies, commercialization costs for WAKIX, and ANDA litigation and settlement expenses. EPX-200 is undergoing pre-IND work, leveraging existing safety and efficacy data for an accelerated development program.
Q:Have the ONSTRIDE 1 and 2 studies begun enrolling patients?
A:The ONSTRIDE 1 and 2 studies are in different stages of site initiation and activation. Enrollment will be posted on clinicaltrials.gov within 21-30 days after the first subject is enrolled.
Q:What is the timeline for decisions in the ongoing litigation? What impact might the litigation have on acceleration clauses in settlements?
A:The timing of the judge’s decision is uncertain, and an appeals process is available to both sides. The litigation process and appeals take time. The company has settled with 6 of 7 generic filers, with generic entry set for March 2030 if pediatric exclusivity is granted. The impact on acceleration clauses was not clarified.
Q:What level of average patient growth is embedded in the 2026 WAKIX guidance? How much contribution is expected from the pediatric cataplexy indication?
A:The 2026 guidance assumes patient growth consistent with 2025, with over 400 patient adds per quarter. The pediatric cataplexy population represents about 5% of the narcolepsy market and is seen as an important addition to the label, providing flexibility for healthcare providers.
Q:What existing clinical data supports pitolisant’s efficacy in fatigue? What is the development timeline for the Phase I PK study?
A:Pitolisant has shown efficacy in fatigue in myotonic dystrophy and OSA studies. The new formulation is undergoing optimization and preparation for a clinical PK study. The histaminergic mechanism of action positions it well for treating fatigue in broader CNS indications.
Q:What are the characteristics and IP status of the new pitolisant formulation?
A:The new formulation may offer differentiated PK parameters suitable for treating fatigue in larger indications. It has an issued patent valid until 2042. The company is exploring other modes of delivery for populations with swallowing dysfunction.
Q:What are the updates on ARGUS and LIGHTHOUSE studies?
A:The ARGUS and LIGHTHOUSE studies are progressing, with top-line data expected in the first half of 2027 and a PDUFA in 2028.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the baseline seizure rates for EPX-100, the exact timing of the judge’s decision in the litigation, and the potential impact of acceleration clauses in settlements. Additionally, they did not clarify the exact level of contribution expected from the pediatric cataplexy indication or provide detailed enrollment updates for ONSTRIDE 1 and 2 studies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CNS indication
EPX
Executive VP
HD placebo
Harmony Biosciences
III study
III trial
IP
NDA submission
ONSTRIDE
Phase III
Phase PK
TEMPO study
VP Chief
WAKIX generation
age narcolepsy
approval
arm trial
blockbuster
brain
cataplexy patient
exclusivity track
field
franchise history
indication formulation
indication orphan
mechanism approach
opportunity CNS
placebo week
process
reduction seizure
stage Phase
status
submission PDUFA
team
today Harmony
track NDA
trial CNS
year age
HRMY Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary highlights strong financial performance and optimistic future guidance, particularly with WAKIX's blockbuster revenue projection and robust pipeline advancements. The Q&A session reveals management's strategic focus on expanding CNS indications and protecting IP, despite some uncertainties in litigation and business development. The market cap suggests moderate sensitivity to news, and the overall sentiment is positive, driven by promising product developments and strategic plans. The company's efforts to address analyst concerns and legal challenges indicate a proactive approach, supporting a positive stock price movement prediction.
Harmony Biosciences Holdings, Inc. (HRMY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Neutral4-14
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call reflects strong financial health and strategic growth, with raised revenue guidance and successful product developments. Despite competitive pressures and litigation uncertainties, the company maintains robust cash reserves. The Q&A section highlights a proactive approach to potential risks, with strategic settlements and ongoing R&D investments. The raised revenue guidance and strategic pipeline advancements contribute to a positive outlook, likely resulting in a 2-8% stock price increase.
HRMY Slides
HRMY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
